Convertible Preferred Stock [Text Block]
Convertible Preferred Stock
The entire disclosure for convertible preferred stock.
Basis of Accounting and Consolidation [Policy Text Block]
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also includes the disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
Basis of Presentation and Consolidation
Antibody Targeted Nanotherapeutic Program with Chemotherapy Drug [Member]
Represents information pertaining to antibody-targeted nanotherapeutic program that contains a chemotherapy drug.
Antibody-targeted nanotherapeutic program with chemotherapy drug
Nanotherapeutic Program with Chemotherapy Drug [Member]
Represents information pertaining to nanotherapeutic program that contains a chemotherapy drug.
Nanotherapeutic program with chemotherapy drug
Operating Leases Reimbursements Received for Tenant Improvements
Tenant improvement reimbursements received
Represents the amount received for tenant improvements agreed to be reimbursed by landlord under the lease agreement.
Business Acquisition Contingent Consideration Period for Issuance of Additional Shares
Period for issuance of additional shares as contingent consideration
Represents the period for issuance of additional shares under the contingent consideration arrangement in a business combination.
Award Type [Axis]
Gain recognized on settlement of contingent consideration
Represents the amount of gain recognized as a result of settlement of contingent consideration in a business combination.
Business Acquisition Contingent Consideration Settlement Gain
Share Based Compensation Arrangements by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]
Weighted Average Remaining Contractual Term
Debt Instrument Unamortized Discount Recorded as Long Term Liability
Discount on loan recorded as a long-term liability to be paid upon full repayment or maturity of the loans
Represents the amount of debt discount that was recorded as a long-term liability to be paid upon full repayment or maturity of the loan that has yet to be amortized.
Represents the amount of debt discount related to costs reimbursed by the entity that has yet to be amortized.
Debt Instrument Unamortized Discount Related to Costs Reimbursed
Discount on loans related to costs reimbursed by the entity
Debt Maturities Repayments Interest Included in Payments
Represents the interest payments included in the future minimum payments not currently in carrying value.
Less interest
Amendment Flag
Discount on automatic conversion into the next qualifying equity financing (as a percent)
Represents the percentage discount on automatic conversion of debt instrument into next qualifying equity financing, if prior to maturity, the entity enters into qualifying financing resulting in a specified amount of gross proceeds.
Debt Instrument Discount on Automatic Conversion into Next Qualifying Equity Financing if Certain Conditions are Met
The percentage points subtracted from the alternative interest rate calculation used to compute the variable rate of the debt instrument.
Percentage points subtracted from alternative interest rate
Debt Instrument Basis Reduction on Variable Rate
Debt Instrument Gross Proceeds in One or More Transactions Prior to Specified Date
Amount of gross proceeds in one or more transactions prior to December 1, 2013 that the Company may elect to extend the interest-only period by six months
Represents the amount of gross proceeds in one or more transactions prior to December 1, 2013 that the Company may elect to extend the interest-only period by six months so that the aggregate outstanding principal balance of the loan would be repaid in monthly installments starting on June 1, 2014 and continuing through November 1, 2016.
Debt Instrument Gross Proceeds from Equity Financing Prior to Maturity Holders of Notes Automaticaly Qualify for Discount
Amount of gross proceeds from qualifying equity financing in which holders would automatically convert into the next qualifying equity financing at a 25% dicount
Represents the amount of gross proceeds from a qualifying equity financing, in which holders of the notes would automatically convert into the next qualifying equity financing at a discount.
Value of the Company's equity securities available for purchase by the lender
Represents the value of the Company's equity securities sold to institutional accredited investors in a private financing, available for purchase by the lender within one year after the closing of the Loan Agreement.
Debt Instrument Lender Option to Purchase Equity Securities
Debt Instrument Lender Option to Purchase Equity Securities Period
Period to purchase equity securities sold to institutional accredited investors under the Loan Agreement
Represents the period to purchase equity securities sold to institutional accelerated investors under the Loan Agreement.
Represents the exercise price for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards.
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price
Exercise Price (in dollars per share)
Arrangements and Non-arrangement Transactions [Domain]
Share Based Compensation, Arrangement by Share Based Payment, Award Options, Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value
Exercise Price $1.25
Represents the exercise price 1.25 dollars per share.
Exercise Price Dollars 1.25 [Member]
Exercise Price Dollars 1.71 [Member]
Exercise Price $1.71
Represents the exercise price 1.71 dollars per share.
Exercise Price Dollars 1.81 [Member]
Exercise Price $1.81
Represents the exercise price 1.81 dollars per share.
Exercise Price Dollars 2.12 [Member]
Exercise Price $2.12
Represents the exercise price 2.12 dollars per share.
Exercise Price Dollars 2.19 [Member]
Exercise Price $2.19
Represents the exercise price 2.19 dollars per share.
Exercise Price Dollars 2.47 [Member]
Exercise Price $2.47
Represents the exercise price 2.47 dollars per share.
Exercise Price Dollars 2.59 [Member]
Exercise Price $2.59
Represents the exercise price 2.59 dollars per share.
Exercise Price Dollars 2.69 [Member]
Exercise Price $2.69
Represents the exercise price 2.69 dollars per share.
Current Fiscal Year End Date
Exercise Price Dollars 5.54 [Member]
Exercise Price $5.54
Represents the exercise price 5.54 dollars per share.
Exercise Price Dollars 6.37 [Member]
Exercise Price $6.37
Represents the exercise price 6.37 dollars per share.
Exercise Price Dollars 6.78 [Member]
Exercise Price $6.78
Represents the exercise price 6.78 dollars per share.
Share Based Compensation, Arrangement by Share Based Payment, Award Options, Outstanding [Abstract]
Options outstanding
Share Based Compensation, Arrangement by Share Based Payment, Award Options, Exercisable [Abstract]
Options exercisable
Unrealized Losses
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses
Deferred Tax Assets, Deferred Expense Capitalized Research and Development Costs
Capitalized research and development expenses
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to capitalized research and development costs, which can only be deducted for tax purposes at a later date and which can only be realized, if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.
Operating Loss Carryforwards Attributable to Deductions for Stock Option Compensation
Federal and state net operating loss carryforwards relate to deductions for stock option compensation
Represents the federal and state net operating loss carryforwards related to deductions for stock option compensation.
Valuation Allowance [Roll Forward]
Change in the valuation allowance against the deferred tax assets
Additions
The amount of the additions in the period in the valuation allowance for a specified deferred tax asset.
Valuation Allowance, Deferred Tax Asset Additions
Valuation Allowance, Deferred Tax Asset, Deductions
Deductions
The amount of the deductions in the period in the valuation allowance for a specified deferred tax asset.
Schedule of Tax Incentive Programs [Table]
Table providing information pertaining to tax incentive and credit programs including the incentives and credits received and recognized, terms of the incentive and credit plans, etc.
Document Period End Date
Tax Incentive Program [Axis]
Information by type of tax incentive and credit programs.
Document and Entity Information
Preferred Stock Warrants, Outstanding
Convertible preferred stock warrants (in shares)
Represents the fair value written certificate that gives the holder the right to purchase shares of a stock for a specified price within a specified period of time.
Convertible preferred stock warrants
Represents the unrealized gain or loss on the remeasurement of fair value of preferred stock warrants.
Change in fair value of convertible preferred stock warrants
Gain (loss) on Mark to Market on Preferred Stock Warrants
(Gain) loss on mark-to-market on preferred stock warrants and contingent consideration
Remeasurement of convertible preferred stock warrants
Amortization of Deferred Lease Benefits and Tax Incentives
Amortization of deferred rent and tax incentives
Represents the amortization of deferred lease benefits and tax incentive of the reporting entity during the reporting period.
Increase (Decrease) Deferred Lease Benefits and Tax Incentive
The increase (decrease) during the reporting period in deferred lease benefits and tax incentives yet to be earned and recognized as a reduction of rental expense over the lease term and in the liability reflecting credits yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
Deferred lease benefits and tax incentives
Reclassification of deferred financing costs to stockholders' equity
Represents the amount of deferred financing costs reclassified to stockholders' equity.
Deferred Financing Costs Reclassification to Stockholders Equity
Deferred financing costs netted against the equity proceeds within stockholders' equity
Accrued interest on Series F amount relieved to additional paid-in capital (Note 14)
Represents the accrued interest on unissued preferred stock that was relieved to additional paid-in capital in a noncash transaction.
Accrued Interest on Preferred Stock Relieved to Additional Paid in Capital
Entity [Domain]
Increase (Decrease) Deferred Rent and Tax Incentive
Deferred rent and tax incentives
The increase (decrease) during the reporting period in deferred rent and tax incentives yet to be earned and recognized as a reduction of rental expense over the lease term and in the liability reflecting credits yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
Issuance of Shares from Advance Preferred Stock, Amount
Issuance of shares from Series F amount (Note 14)
Represents the issuance of shares from the amount received in advance in a noncash transaction.
Initial Public Offering
Initial Public Offering Disclosure [Text Block]
Initial Public Offering
The entire disclosure of initial public offering made by company.
License and Collaboration Agreements
Consolidated Subsidiaries
Consolidated Subsidiaries [Text Block]
The entire disclosure related to consolidated subsidiaries of the entity.
Series F Amount
Series F Amount
The entire disclosure for Series F convertible preferred stock.
Series F Amount Disclosure [Text Block]
Stock Warrants Disclosure [Text Block]
Stock Warrants
The entire disclosure for the common stock warrants activity of the company.
Conversion of Stock Warrants
Conversion of convertible preferred stock warrants to common stock warrants
The value of convertible preferred stock warrants converted to common warrants.
Number of Targeted Therapeutic Oncology Candidates in Clinical Development
Number of targeted therapeutic oncology candidates
Represents the number of targeted therapeutic oncology candidates in clinical development of the entity.
Stock Issued During Period Shares Issued to Underwriters under over Allotment Option
Common stock issued to underwriters under an over-allotment option (in shares)
Represents the number of shares issued to underwriters under an over-allotment option.
Common stock issued to underwriters pursuant to the exercise of an over-allotment option (in shares)
Convertible Preferred Stock Warrant [Member]
Convertible preferred stock warrants
Represents the security that gives the holder the right to purchase preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Convertible preferred stock warrants
Sanofi [Member]
Sanofi
Represents the information pertaining to Sanofi.
Phase Two Clinical Trials in Breast Cancer and Nonsmall Cell Lung Cancer [Member]
Phase 2 clinical trials in breast cancer and non-small cell lung cancer
Represents the information pertaining to dosing the first patients in Phase 2 clinical trials in breast cancer and non-small cell lung cancer.
Available-for-sale Securities, Gross Unrealized Gains
Unrealized Gains
Phase Two Clinical Trials in Ovarian Cancer [Member]
Phase 2 clinical trial in ovarian cancer
Represents the information pertaining to dosing the first patient in a Phase 2 clinical trial in ovarian cancer.
Development and regulatory milestone
Development and Regulatory Milestones [Member]
Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.
Sales Milestones [Member]
Sales milestone
Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.
Phase Three Clinical Trials in Pancreatic Cancer [Member]
Phase 3 clinical trial in pancreatic cancer
Represents the information pertaining to dosing the first patient in a Phase 3 clinical trial in pancreatic cancer.
Pharma Engine Inc [Member]
PharmaEngine
Represents the information pertaining to PharmaEngine, Inc.
Related Party Transactions Shares Purchased by Related Party
Shares of common stock purchased by related party in connection with initial public offering
Represents the number of shares of common stock purchased by a related party in connection with the initial public offering.
Schedule of shares reserved for future issuance
Tabular disclosure of the shares of common stock reserved for future issuance by the entity.
Schedule of Shares of Common Stock Reserved for Future Issuance [Table Text Block]
Stock Incentive Plan 2008 [Member]
2008 Plan
Represents the details pertaining to 2008 Stock Incentive Plan as amended, a stock-based compensation plan.
Stock Incentive Plan 2008 Member and Stock Incentive Plan 2011 [Member]
Represents the details pertaining to the 2008 Stock Incentive Plan as amended, and the 2011 Stock Incentive Plan, stock-based compensation plans.
2008 Plan and 2011 Plan
Stock Incentive Plan 2011 [Member]
2011 Plan
Represents the details pertaining to 2011 Stock Incentive Plan, a stock-based compensation plan.
Equity Incentive Plan [Member]
2012 EIP
Represents the details pertaining to the 2012 Equity Incentive Plan, a stock-based compensation plan.
Employee [Member]
Employee
Represents the details pertaining to the employees of the entity.
Employee awards
Non Employee [Member]
Non-employee
Represents the details pertaining to individuals other than employees of the entity.
Convertible Preferred Stock and Convertible Preferred Stock Warrants [Policy Text Block]
Convertible Preferred Stock and Convertible Preferred Stock Warrants
Disclosure of accounting policy for convertible preferred stock and convertible preferred stock warrants.
Available For Sale Securities Expected Maturity Period
Expected average maturities period of marketable securities classified as available-for-sale
Represents the expected average maturity period of marketable securities classified as available-for-sale.
Collaborative Arrangement Revenue Recognition [Abstract]
Recognized revenue under collaboration agreements
Gain (Loss) Related to Settlement
Settlement from former service provider
Represents the amount of gain (loss) related to settlement from a former service provider.
Achievement of Milestone [Axis]
Information by categories of milestones achieved.
Achievement of Milestone [Domain]
Different categories of achievement of milestones.
Collaborative Arrangement Upfront License Fee Received
Upfront license fee received
Represents the cumulative amount of nonrefundable, noncreditable upfront license fee received during the period under the terms of license and collaboration agreements.
Upfront payment
Represents the amount of revenue recognized from upfront payment received during the period under the terms of license and collaboration agreements.
Collaborative Arrangement Revenue Recognized Upfront Payment
Collaborative Arrangement Revenue Recognized Milestone Payment
Milestone payments
Represents the amount of revenue recognized from milestone payment received during the period under the terms of license and collaboration agreements.
Milestone payments earned
Collaborative Arrangement Revenue Recognized Development Services
Development services
Represents the amount of revenue recognized from development services fees received during the period under the terms of license and collaboration agreements.
Manufacturing services and other
Represents the amount of revenue recognized from manufacturing services and other fees received during the period under the terms of license and collaboration agreements.
Collaborative Arrangement Revenue Recognized Manufacturing Services and Other
Represents the cumulative amount of nonrefundable, noncreditable upfront license fees paid during the period under the terms of license and collaboration agreements.
Collaborative Arrangement Upfront Payment Obligation
Upfront license fees paid
Represents the cumulative obligation for milestone payment payable during the period under the terms of license and collaboration agreements.
Maximum milestone payment obligation
Collaborative Arrangement Maximum Milestone Payment Obligation
Collaborative Arrangement Milestone Payment
Milestone payment
Represents the amount of milestone payment made during the period under the terms of license and collaboration agreements.
Milestone payment
Summary of Significant Accounting Policies
Collaborative Arrangement Revenue Recognized
Total
Represents the revenue recognized during the period under the terms of license and collaboration agreements.
Collaboration Agreement Assets and Liabilities [Abstract]
Assets and liabilities related to collaboration agreement
Entity Well-known Seasoned Issuer
Collaborative Arrangement [Abstract]
Collaborative arrangement additional information
Entity Voluntary Filers
Collaborative Arrangement Milestone Payments Received
Milestone payments received
Represents the cumulative amount of milestone payment received during the period under the terms of license and collaboration agreements.
Entity Current Reporting Status
Represents the period of lease for additional space under the amended lease agreement.
Operating Lease Amendment Additional Space Lease Term
Lease term of additional space
Entity Filer Category
Accounts payable, accrued expenses and other
Accounts Payable and Accrued Liabilities, Current
Total accounts payable, accrued expenses, and other
Collaborative Arrangement Expected Development Period
Expected development period from the effective date of agreement
Represents the expected development period from the effective date of agreement.
Entity Public Float
Maximum reimbursement for tenant improvements agreed by landlord
Represents the maximum amount of tenant improvements agreed to be reimbursed by landlord under the lease agreement.
Operating Leases Maximum Reimbursement for Tenant Improvements
Entity Registrant Name
Collaborative Arrangements Reimbursement of Previously Billed Amount
Previously billed amount the Company will reimburse
Represents the previously billed amount the Company will reimburse the other party under the license and collaboration agreement.
Entity Central Index Key
Collaborative Arrangement Reduction in Earnings Due to Reimbursement of Previously Billed Amount
Reduction in earnings due to reimbursement of previously billed amounts
Represents the amount of reduction in earnings due to reimbursement of previously billed amount under the license and collaboration agreement.
Other Nonoperating Income Expense [Policy Text Block]
Disclosure of accounting policy for other income and expenses.
Other Income (Expense)
Silver Creek Pharmaceuticals Inc [Member]
Silver Creek
Represents information pertaining to Silver Creek Pharmaceuticals Inc., a subsidiary of the entity.
As of the reporting date, the fair value of noncontrolling interest (deficit). The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.
Non-controlling interest (deficit)
Noncontrolling Interest Equity Preferred Fair Value
Entity Common Stock, Shares Outstanding
Proceeds from Issuance Initial Public Offering, Net of Offering Costs
The cash inflow associated with the amount received from entity's first offering of stock to the public, net of offering costs.
Net proceeds from initial public offering
The cash inflow associated with the amount received from entity's first offering of stock to the public, net of offering costs, less the amount of deferred financing costs that were reclassified to equity.
Proceeds from Issuance Initial Public Offering Net of Offering Costs Less Deferred Financing Costs Reclassified to Equity
Proceeds from initial public offering, net of offering costs
Schedule of Employee and Nonemployee Service Share Based Compensation Allocation of Recognized Period Costs [Text Block]
Tabular disclosure of the allocation of equity-based compensation costs for employee and non-employee awards to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
Schedule of recognized stock-based compensation expense
The different names of stock transactions and the different attributes of each transaction.
Sale of Stock [Table]
Public Offering
Sale of Stock [Line Items]
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Allocated Share Based Compensation Expense Including Non Employees
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees.
Total stock-based compensation expense
Operating Leases Future Minimum Payments Due Amendment
Represents the amount of required minimum rental payments for leases having an initial or remaining non-cancelable term in excess of one year related to the lease amendment.
Aggregate rent due over amended term of lease
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accounts Payable, Accrued Expenses and Other
The amount of purchased premiums and interest on available-for-sale securities.
Purchased premiums and interest on available-for-sale securities
Purchased Premiums and Interest on Available For Sale Securities
Number of common shares reserved for future issuance related to convertible preferred stock warrants.
Convertible preferred stock warrants
Convertible Preferred Stock Warrants Shares Reserved for Future Issuance
Number of common shares reserved for future issuance related to common stock warrants.
Common stock warrants (in shares)
Common Stock Warrants Shares Reserved for Future Issuance
Accounts payable, accrued expenses and other
Accounts Payable and Accrued Liabilities, Current [Abstract]
Common Stock Disclosure [Text Block]
Common Stock
The complete disclosure pertaining to the entity's common stock.
Hermes Bio Sciences Inc [Member]
Hermes
Represents information pertaining to HermesBioSciences,Inc., a privately-held biotechnology company developing lipidic nano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy.
Antibody Targeted Nanotherapeutic [Member]
An antibody-targeted nanotherapeutic
Represents an antibody-targeted nanotherapeutic development program which contains a chemotherapy drug.
Nanotherapeutic [Member]
Nanotherapeutic
Represents the nanotherapeutic development program which contains a chemotherapy drug.
Other Programs [Member]
Other programs
Represents the other development programs.
Required disclosures pertaining to research and development program.
Research and Development Program [Axis]
Research and Development Program [Domain]
Represents information by category of different research and development program.
Document Fiscal Year Focus
Number of Geographic Segments
Number of geographic segments
Number of geographic segments. A geographic segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other units located at different geographic location of the same enterprise), (b) whose results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available.
Document Fiscal Period Focus
Number of Issues to Limit Investment Amount as per Investment Policy
Number of issues with limited investment as per investment policy
Represents the number of issues in which entity will limit its investment as per investment policy so as to reduce the credit risk.
GTC
Represents information pertaining to GTC Biotherapeutics, Inc.
GTC Biotherapeutics Inc [Member]
Collaborative Arrangement License Consideration Shares
Shares received as consideration under the license agreement
Represents the shares received as a consideration under the license agreement.
Collaborative Arrangement License Consideration Shares Fair Value
Fair value of shares received as consideration under the license agreement
Represents the fair value of shares received as a consideration under the license agreement.
Inprocess Research and Development Program [Axis]
Information by different types of research and development programs in process.
Inprocess Research and Development Program [Domain]
Different types of research and development programs in process.
Core Nano Carrier Technology [Member]
Core nano-carrier technology
Represents information pertaining to core nano-carrier technology.
Acquired Inprocess Research and Development
Acquired IPR&D recognized in a business combination
The aggregate amount of acquired in-process research and development recognized as part of a business combination.
Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Excluding Goodwill
Total identifiable net assets
The amount of acquisition cost of a business combination allocated to assets acquired, net of liabilities assumed.
Business Acquisition Purchase Price Allocation in Process Research and Development Acquired Discount Rate
Discount rate used to assign value to acquired IPR&D
Represents the company specific discount rate used to assign values to in-process research and development acquired as a part of business acquisition.
Additional shares purchased by parent company related to initial purchase
Represents the purchase by the parent of additional equity shares in a subsidiary during the period related to an initial purchase.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Addition Initial Purchase of Interest by Parent Shares
Legal Entity [Axis]
Minority Interest Increase from Stock Issuance Shares
Shares issued to other investors
Represents an increase in noncontrolling interest from issuance of additional equity shares to noncontrolling interest holders.
Document Type
Minority Interest Ownership Percentage by Employees and Directors of Parent
Shares owned by employees and directors of the parent company (as a percent)
Represents the percentage of shares owned by employees and directors of the parent company.
Other Inprocess Research and Development Program [Member]
Other in-process research and development programs
Represents information pertaining to other in-process research and development programs.
Tabular disclosure of the components of property, plant and equipment.
Schedule of Property, Plant and Equipment Components [Table Text Block]
Schedule of property and equipment
Proceeds from Issuance of Convertible Preferred Stock of Subsidiary
Proceeds from issuance of convertible preferred stock of Silver Creek Pharmaceuticals, Inc.
The cash inflow from issuance of preferred stocks of a majority owned subsidiary, identified as being convertible into another form of financial instrument, typically the entity's common stock.
Proceeds from convertible notes issued by subsidiary, net of issuance costs
Stock Issued During Period Value Warrants Exercised
Exercise of common stock warrants
Gross value of stock (or other type of equity) issued during the period as a result of exercise of common stock warrants.
Accounts Payable and Accrued Liabilities, Noncurrent
Accrued interest
Stock Issued During Period Shares Warrants Exercised
Exercise of common stock warrants (in shares)
The number of shares of stock issued during the period pursuant to the exercise of warrants.
Number of common stock issued (in shares)
Conversion of Preferred Stock Warrants to Common Stock Warrants Value
Conversion of convertible preferred stock warrants to common stock warrants
Value of common stock warrants issued during the period into equity upon the conversion of preferred stock warrants in mezzanine equity.
Conversion of Preferred Stock Warrants to Common Stock Warrants Shares
Conversion of preferred stock warrants to common stock warrants (in shares)
Number of common stock warrants issued during the period upon the conversion of preferred stock warrants.
Adjustments to Additional Paid in Capital Change in Par Value
Change in par value
Adjustment to additional paid-in-capital resulting from change in par value of common stock issued.
Proportion of Outstanding Votes Required for Specified Event Not to be Deemed Liquidation
Proportion of outstanding votes required for a specified event not to be a deemed liquidation
Represents the proportion of outstanding votes required for a specified event not to be a deemed liquidation.
Temporary Equity Redemption Value as Percentage of Purchase Price
Redemption price as a percentage of purchase price
Represents the redemption price of temporary equity as a percentage of purchase price.
Initial Public Offering Share Price as Percentage of Conversion Price to Trigger Automatic Conversion of Preferred Shares
OLD Minimum offering price per share in an initial public offering expressed as a percentage of the conversion price to trigger automatic conversion of preferred shares to common shares
Represents the offering price per share in an initial public offering expressed as a percentage of the conversion price that would trigger an automatic conversion of preferred shares to common shares.
Initial Public Offering Share Price As Percentage Of Series C Convertible Preferred Stock Conversion Price To Trigger Automatic Conversion Of Preferred Shares
Represents the offering price per share in an initial public offering, expressed as a percentage of the conversion price of the Series C convertible preferred stock, that would trigger an automatic conversion of all outstandig convertible preferred shares to common shares.
Minimum offering price per share in an initial public offering expressed as a percentage of the Series C conversion price to trigger automatic conversion of preferred shares to common shares
Temporary Equity Shares Intended to be Authorized Under 2007 Plan
Shares intended to be authorized under the 2007 Restated Articles
Represents the shares intended to be authorized under the 2007 restated articles of the organization.
Imputed Noncash Interest Expense
Imputed noncash interest expense
Represents the recorded imputed noncash interest expense pertaining to delayed delivery of convertible stock.
Represents information pertaining to series C preferred stock warrant.
Series C Preferred Stock Warrant [Member]
Series C preferred stock warrant
Common Stock Warrant [Member]
Common stock warrant
Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Series D Preferred Stock Warrant [Member]
Series D preferred stock warrant
Represents information pertaining to series D preferred stock warrant.
Class of Warrant or Right Outstanding [Roll Forward]
Warrants for the purchase of stock
Class of Warrant or Right Expired
Expired (in shares)
Aggregate amount of each class of warrants or rights expired during the period.
Class of Warrant or Right Exercised
Exercised (in shares)
Aggregate amount of each class of warrants or rights exercised during the period.
Class of Warrant or Right Conversion
Conversion (in shares)
Aggregate amount of each class of warrants or rights converted to common stock warrants during the period.
Weighted average exercise price
Class of Warrant or Right Outstanding Weighted Average Exercise Price [Roll Forward]
Class of Warrant or Right Exercise Price of Warrants or Rights Expired
Expired (in dollars per share)
The exercise price of each class of warrants or rights expired during the period.
Class of Warrant or Right Exercise Price of Warrants or Rights Exercised
Exercised (in dollars per share)
The exercise price of each class of warrants or rights exercised during the period.
Class of Warrant or Right Exercise Price of Warrants or Right Converted
Conversion (in dollars per share)
The exercise price of each class of warrants or rights converted to common stock warrant during the period.
Class of Warrant or Right Outstanding Additional Disclosure [Abstract]
Additional disclosure
Class of Warrant or Right Warrants Held by Related Party Modified Expiration Period and Exercise Price
Number of warrants held by related party in which expiration and exercise price was modified (in shares)
Represents the number of warrants held by the related party in which the expiration period and exercise price was modified.
Accounts payable, accrued expenses and other
Accounts Payable, Current
Accounts payable
Class of Warrant or Right Warrant Held by Related Party Extended Expiration Period
Extended period of extension
Represents the period by which expiration date is extended for warrants held by the related party.
Class of Warrant or Right Exercise Price of Warrants Held by Related Party Before Modification One
Exercise price before modification, one (in dollars per share)
Represents the first exercise price of warrants held by related party before modification.
Class of Warrant or Right Exercise Price of Warrants Held by Related Party Before Modification Two
Exercise price before modification, two (in dollars per share)
Represents the second exercise price of warrants held by related party before modification.
Class of Warrant or Right Warrants Held by Related Party Exercise Price
Exercise price of warrants held by related party (in dollars per share)
The exercise price of each class of warrants or rights outstanding, held by the related party.
Adjustments to Additional Paid in Capital Increase in Exercise Price of Warrants
Incremental value of warrants accounted within additional paid-in capital
Adjustment to additional paid in capital as a result of the increase in the exercise price of the warrants.
Class of Warrant or Right Exercised Cashless
Number of warrants cashless exercised (in shares)
Represents the number of cashless warrants exercised.
Common Stock Shares Issued Cashless
Number of common stock issued as a result of cashless exercise of warrants (in shares)
The number of shares of common stock issued during the period as a result of the cashless exercise of warrants.
Type of tax incentive and credit programs.
Tax Incentive Program [Domain]
Amounts payable related to the agreement
Accounts Payable
Life Sciences Tax Incentive Program 2010 [Member]
Life Sciences Tax Incentive Program 2010
Represents information pertaining to tax incentives awarded in 2010 under the Life sciences Tax Incentive program.
Life Sciences Tax Incentive Program 2011 [Member]
Life Sciences Tax Incentive Program 2011
Represents information pertaining to tax incentives awarded in 2011 under the Life sciences Tax Incentive program.
Accounts receivable
Accounts Receivable [Member]
Federal Qualifying Therapeutic Discovery Projects Program [Member]
Qualifying Therapeutic Discovery Projects
Represents information pertaining to the Qualifying Therapeutic Discovery Projects program.
Federal Qualifying Therapeutic Discovery Projects program
Tax Incentive Program [Line Items]
Tax incentive program
Summary of significant accounting policies
Tax Incentive Program Tax Incentive Awarded
Tax incentive awarded
Represents the amount of tax incentives awarded under the tax incentive and credit programs.
Tax Incentive Program State Research and Development Tax Credits Monetized
State research and development tax credits monetized
Represents the state research and development tax credits monetized under the tax incentive and credit programs.
Tax Incentive Program Number of Employees Pledged to be Hired
Number of incremental employees pledged to be hired
Represents the number of employees to be hired under the incentive program over a specified period of time.
Tax Incentive Program Performance Period
Performance period
Represents the performance period of the tax incentive program over which the incentive is to be amortized.
Tax Incentive Program Benefit Recognized
Amount of benefit recognized
Represents the portion of tax incentives and grants received under the tax incentive and credit programs, recognized during the period.
Tax Incentive Program Grants Awarded
Grants awarded
Represents the amount of grants awarded as tax incentive under the tax incentive and credit programs.
Tax Incentive Program Grant Received
Grants received
Represents the amount of grants received.
Operating Lease Amendment Additional Space
Additional space that the entity will occupy under the amended lease agreement
Represents the additional space that the entity will occupy under the amended lease agreement.
Operating Lease Amendment Aggregate Space
Aggregate space that the entity will occupy under the amended lease agreement
Represents the aggregate space that the entity will occupy under the amended lease agreement.
Operating Leases, Reimbursement for Tenant Improvements in Remainder of Fiscal Year
Reimbursement for tenant improvements agreed by landlord in 2012
Represents the amount of tenant improvements to be reimbursed by the landlord under the lease agreement during remainder of the current fiscal year.
Reimbursement for tenant improvements agreed by landlord in 2013
Represents the amount of tenant improvements to be reimbursed by the landlord under the lease agreement within the second year from the balance sheet date.
Operating Leases, Maximum Reimbursement for Tenant Improvements in Fiscal Year Two
Accretion (Amortization) of Discounts and Premiums, Investments
Amortization of premium on available-for-sale securities
Operating Leases, Maximum Reimbursement for Tenant Improvements in Fiscal Year Three
Reimbursement for tenant improvements agreed by landlord in 2014
Represents the amount of tenant improvements to be reimbursed by the landlord under the lease agreement within the third year from the balance sheet date.
Operating Leases, Reimbursement for Tenant Improvements Recorded in Prepaid Expenses and Other Current Assets
Reimbursement for tenant improvements agreed by landlord recorded in prepaid expenses and other current assets with offsetting entry to deferred rent
Represents the amount of reimbursement for tenant improvements agreed by the landlord recorded in prepaid expenses and other current assets with an offsetting entry recorded to deferred lease benefits.
Represents the amount of reimbursement for tenant improvements agreed by the landlord recorded in other assets with an offsetting entry recorded to deferred lease benefits.
Operating Leases, Reimbursement for Tenant Improvements Recorded in Non Current Assets
Reimbursement for tenant improvements agreed by landlord recorded in other assets with offsetting entry to deferred rent
Operating Lease, Amended Lease Renewal Period Option One
Additional period of renewal of amended lease with respect to entire leased space, option one
Represents the additional period of renewal of amended lease with respect to the entire leased space, option one.
Represents the additional period of renewal of amended lease with respect to the entire leased space, option two.
Operating Lease, Amended Lease Renewal Period Option Two
Additional period of renewal of amended lease with respect to entire leased space, option two
Operating Leases, Future Minimum Payments Due in Five Years and Thereafter
2017 and later
Amount of required minimum rental payments maturing in the fifth fiscal year and thereafter, following the latest fiscal year for operating leases having initial or remaining non-cancelable letter-terms in excess of one year.
Hercules Technology Growth Capital Inc [Member]
Hercules Technology Growth Capital, Inc.
Represents information pertaining to Hercules Technology Growth Capital, Inc. ("Hercules").
Additional term loan which closed on December 14, 2012
Debt Instrument, Additional Advance
Represents the additional term loan advance.
Additional term loan
Debt Instrument Interest Only Payment Period
Period of interest-only payment
Represents the period of interest-only payment as provided under the loan agreement.
Debt Instrument Interest Only Payment Period Extension
Extension period for interest only payments
Represents the extension period for interest only payments as provided under the loan agreement.
Schedule of Common Stock Warrant Activity [Table Text Block]
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for common stock warrants that were outstanding at the beginning and end of the year, and common stock warrants granted, exercised and expired during the year.
Schedule of common stock warrant activity of the Company
Schedule of Preferred Stock Warrant Activity [Table Text Block]
Schedule of preferred stock warrant activity of the Company
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for preferred stock warrants that were outstanding at the beginning and end of the year, and preferred stock warrants granted, exercised and expired during the year.
Milestone payment triggered
Represents the cumulative obligation for milestone payment payable during the period under the terms of license and collaboration agreements.
Collaborative Arrangement Milestone Payment Obligation
Temporary Equity Increase From Initial Purchase Of Preferred Stock Of Subsidiary
Increase in temporary equity from initial purchase of preferred stock of subsidiary.
Ownership change in non-controlling interest
Acquisition of Silver Creek preferred stock
Series F amount interest
Adjustments to Additional Paid in Capital Accrued Non Cash Interest Related to Series F 2010 Exchange Agreement
The adjustment to additional paid in capital for the imputed cash noncash interest expense related to the Series F exchange agreement.
Accrued noncash interest expense recorded as additional paid-in capital
Temporary Equity Components [Axis]
Information by component of temporary equity.
Temporary Equity Components [Domain]
Identification of the components of temporary equity.
Temporary Equity Stock Issued During Period Shares New Issues
Issuance of stock (in shares)
Number of new shares classified as temporary equity issued during the period.
Number of shares issued
Gross value of stock (or other type of equity) issued during the period as a result of exercise of warrants.
Temporary Equity Stock Issued During Period Value Warrants Exercised
Issuance of stock as a result of warrant exercises
The number of shares of stock issued during the period pursuant to the exercise of warrants.
Temporary Equity Stock Issued During Period Shares Warrants Exercised
Issuance of stock as a result of warrant exercises (in shares)
Initial term loan advance
Debt Instrument, Initial Advance
Represents the initial term loan advance.
Debt Instrument Interest Rate Alternative One [Member]
First alternative interest rate
Represents the first alternative interest rate.
Debt Instrument Interest Rate Alternative [Domain]
Identification of the alternative interest rate that may be used to calculate the interest rate of the debt instrument.
Other Commitments [Domain]
Other future obligation.
Debt Instrument Interest Rate Alternative Two [Member]
Second alternative interest rate
Represents the second alternative interest rate.
Debt Instrument Interest Rate Alternative [Axis]
The alternative interest rate that may be used to calculate the interest rate of the debt instrument.
Debt Instrument Interest Rate Stated Percentage Used as Basis for Calculation of Alternative Interest Rate
Stated percentage used as basis for calculation of alternative interest rate
Represents the stated interest rate used as the basis for calculation of the alternative interest rate.
Initial Public Offering Share Price to Trigger Automatic Conversion of Preferred Shares
Minimum offering price per share in an initial public offering to trigger automatic conversion of preferred shares to common shares
Represents the minimum offering price per share in a initial public offering that would trigger an automatic conversion of preferred shares to common shares.
Initial Public Offering Gross Proceeds to be Received Upon Firm Commitment to Trigger Automatic Conversion of Preferred Shares
Represents the gross proceeds to be received upon the firm commitment underwritten initial public offering which would trigger all outstanding preferred shares to be automatically converted to shares of common stock.
Aggregate gross proceeds from an initial public offering that would trigger automatic conversion of preferred shares to common shares
Initial Public Offering Divedend to be Decalred and Paid on Automatic Conversion of Preferred Shares
Dividend to be declared and paid in cash on automatic conversion of preferred shares
Represents the amount of dividend to be declared and paid on automatic conversion of preferred shares.
Temporary Equity Share Price Initial Investment
The per share price representing the initial investment of preferred stock.
Initial investment recorded as convertible preferred stock (in dollars per share)
Schedule of Common and Preferred Stock Warrant Activity [Table Text Block]
Schedule of common and convertible preferred stock warrant activity of the Company
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for common and preferred stock warrants that were outstanding at the beginning and end of the year, and common stock warrants granted, exercised and expired during the year.
Preferred Stock Warrant [Member]
Preferred stock warrant
Security that gives the holder the right to purchase shares of preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
Operating Leases Future Minimum Payments Due in Six Years and Thereafter
2018 and thereafter
Amount of required minimum rental payments maturing in the sixth fiscal year and thereafter, following the latest fiscal year for operating leases having initial or remaining non-cancelable letter-terms in excess of one year.
Interest Expense Cash
Cash interest expense
The cost of borrowed funds accounted for as cash interest that was charged against earnings during the period.
Interest Expense Non Cash
Non cash interest expense
The cost of borrowed funds accounted for as non cash interest that was charged against earnings during the period.
Represents the period to terminate the license agreement.
Collaborative Arrangement License Termination Period
License agreement termination period
Represents the additional revenue recognized during the period under the terms of the license agreement due to a change in estimate.
Collaborative Arrangement Additional Revenue Due to Change in Estimate
Additional revenue recongnized due to a change in estimate
Life Sciences Tax Incentive Program 2013 [Member]
Life Sciences Tax Incentive Program 2013
Represents information pertaining to tax incentives awarded in 2013 under the Life Sciences Tax Incentive Program.
Interest Payable Noncurrent
Accrued interest
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables that has been incurred through that date and due after one year (or beyond the operating cycle, if longer) and is unpaid.
Decrease in Restricted Cash
Release of restricted cash
The net cash outflow for the decrease associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
Derivative Liability Issued
Issuance of derivative liability
Represents the fair value of derivative liability issued in noncash investing and financing activities.
Goodwill
Goodwill [Abstract]
Assignment of restricted cash
The net cash inflow for the increase associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
Increase In Restricted Cash
Represents information pertaining to directors, officers, scientific advisory board members and related parties.
Management and Other Related Parties [Member]
Directors, officers, scientific advisory board members and related parties
Other Commitments [Axis]
Information by type of other commitment.
Short Term Borrowings before Discount
Represents the aggregate carrying amount of short-term borrowings as of the balance sheet date before deducting unamortized discount.
Total convertible notes outstanding at the end of the period
Collaboration Revenue [Member]
Aggregate revenue during the period from collaboration agreements.
Collaboration revenues
Components of accounts payable, accrued expenses and other.
Accounts Payable, Accrued Expenses and Other [Table]
Accounts Payable, Accrued Expenses and Other [Line Items]
Accounts payable, accrued expenses and other
Schedule Of Debt Instruments [Table]
A table or schedule providing information pertaining to short-term and long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation.
Schedule of Interest Expense Debt [Table Text Block]
Summary of the interest expense the Company incurred on loans payable, convertible notes payable, and other interest expense
Tabular disclosure of interest cost incurred during the period.
Probability Weighted Valuation Technique [Member]
Probability-weighted
Probability weighted valuation technique used to measure fair value.
Discounted Cash Flow Valuation Technique [Member]
Discounted cash flow technique
Discounted cash flow valuation technique used to measure fair value.
Fair Value Inputs Qualified Equity Financing
Gross proceeds from qualified equity financing
Represents the gross proceeds from qualified equity financing, defined as a sale or series of related sales of equity securities used as an input to measure fair value.
Accrued Liabilities, Current
Accrued expenses and other
Total accounts payable, accrued expenses and other
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less: Accumulated depreciation and amortization
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Amortization period of intangible asset acquired
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life
Amortization period of core technology acquired from Hermes
Acquired Finite-lived Intangible Asset, Amount
Acquired intangible assets
Additional paid-in capital
Additional Paid in Capital
Additional paid-in capital
Additional Paid-in Capital [Member]
Adjustments to Additional Paid in Capital, Reallocation of Noncontrolling Interest
Ownership change in non-controlling interest
Adjustments to reconcile net loss to net cash used in operating activities
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Stock-based compensation
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Stock-based compensation expense for employee awards
Allocated Share-based Compensation Expense
Amortization
Amortization of Intangible Assets
Amortization of Financing Costs
Amortization of the liability component of the debt issuance costs
Amortization of Debt Discount (Premium)
Amortization of the debt discounts
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Potentially dilutive securities (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares
Antidilutive Securities, Name [Domain]
Antidilutive Securities [Axis]
Asset Impairment Charges
Impairment charges
Recognized impairment charges
Current assets:
Assets, Current [Abstract]
Assets
Assets [Abstract]
Total current assets
Assets, Current
Assets Held under Capital Leases [Member]
Property and equipment under capital leases
Total assets
Assets
Total assets of consolidated subsidiaries
Assets, Fair Value Disclosure [Abstract]
Assets
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Aggregate fair value, Due within 1 year
Aggregate Fair Value
Available-for-sale Securities, Fair Value Disclosure
Investments
Fair Value
Available-for-sale Securities, Gross Unrealized Losses
Unrealized Losses
Available-for-sale Securities, Debt Maturities, Amortized Cost Basis
Amortized Cost
Available-for-sale Securities, Gross Realized Gain (Loss)
Realized gains (losses) recognized on the sale or maturity of securities
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions
Number of securities in unrealized loss position for less than 12 months
Basis of Accounting, Policy [Policy Text Block]
Basis of presentation and consolidation
Billed Contracts Receivable
Accounts receivable, billed
Accounts payable
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable
Number of additional shares that could have been required to be issued as contingent consideration
Business Acquisition, Contingent Consideration, Shares Issuable
Prepaid expenses
Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets
Business Acquisition [Axis]
Business Acquisition, Pro Forma Information [Abstract]
Unaudited pro forma summary
Contingent consideration
Business Acquisition, Contingent Consideration, at Fair Value
Goodwill
Business Acquisition, Purchase Price Allocation, Goodwill Amount
Research and development revenues
Business Acquisition, Pro Forma Revenue
Accrued expenses
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities
Business Acquisition, Acquiree [Domain]
Schedule of unaudited pro forma summary
Business Acquisition, Pro Forma Information [Table Text Block]
Total net assets
Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net
Recognized amounts of identifiable assets acquired and liabilities assumed:
Business Acquisition, Purchase Price Allocation [Abstract]
Cash acquired
Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents
Net loss
Business Acquisition, Pro Forma Net Income (Loss)
Shares of common stock issued
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares
Consolidated Subsidiaries
Deferred tax liabilities, net of deferred tax assets
Business Acquisition, Purchase Price Allocation, Deferred Taxes Asset (Liability), Net, Noncurrent
Common shares of Merrimack Pharmaceuticals, Inc.
Business Acquisition, Cost of Acquired Entity, Equity Interests Issued and Issuable
Acquired In-process Research and Development
Business Acquisition [Line Items]
Consolidated subsidiaries
Goodwill and intangible assets, net
Fair value of consideration transferred
Business Acquisition, Cost of Acquired Entity, Purchase Price
Other long-term assets
Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets
Fair value of consideration transferred:
Business Combination, Consideration Transferred [Abstract]
Contingent consideration
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
Changes in property and equipment in accounts payable and accrued expenses
Capital Expenditures Incurred but Not yet Paid
Capital lease obligations
Capital Lease Obligations, Current
Cash and Cash Equivalents Disclosure [Text Block]
Cash equivalents
Cash equivalents
Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Cash, Cash Equivalents and Restricted Cash
Cash equivalents
Cash, Cash Equivalents and Restricted Cash
Unrestricted cash and cash equivalents and available-for-sale securities
Cash, Cash Equivalents, and Short-term Investments
Certificates of deposit
Certificates of Deposit [Member]
Class of Warrant or Right [Table]
Balance at the beginning of the period (in shares)
Balance at the end of the period (in shares)
Class of Warrant or Right, Outstanding
Class of Warrant or Right [Line Items]
Stock warrants
Class of Warrant or Right [Domain]
Class of Warrant or Right [Axis]
Balance at the beginning of the period (in dollars per share)
Balance at the end of the period (in dollars per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights
Class of Stock [Domain]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License and collaboration agreements
Contractual matter
Collaborative Arrangement Disclosure [Text Block]
License and Collaboration Agreements
Collaborative Arrangement [Member]
License and Collaboration Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]
Collaborative Arrangements and Non-collaborative Arrangements [Axis]
Commercial paper
Commercial Paper [Member]
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Commitments and Contingencies
Commitments and contingencies (Note 10)
Commitments and Contingencies.
Common stock
Common Stock [Member]
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Common stock, outstanding shares
Common stock, $0.01 par value: 200,000 shares authorized at December 31, 2012 and March 31, 2013; 95,825 and 95,948 shares issued and outstanding at December 31, 2012 and March 31, 2013, respectively
Common Stock, Value, Issued
Common stock, shares issued
Common Stock, Shares, Issued
Balance (in shares)
Balance (in shares)
Common stock, issued shares
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized
Common Stock, Shares Authorized
Common stock, authorized shares
Number of authorized shares of common stock
Common Stock, Capital Shares Reserved for Future Issuance
Shares reserved for future issuance
Shares reserved for future issuance
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Retirement Plan
Compensation and Employee Benefit Plans [Text Block]
Retirement Plan
Temporary differences that give rise to significant net deferred tax assets
Components of Deferred Tax Assets and Liabilities [Abstract]
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Comprehensive income (loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Loss
IT equipment
Computer Equipment [Member]
Concentration Risk Type [Domain]
Concentration of Credit Risk
Concentration Risk [Line Items]
Concentration Risk Benchmark [Domain]
Concentration Risk [Table]
Concentration Risk Benchmark [Axis]
Concentration of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration Risk Type [Axis]
Concentration risk (as a percent)
Concentration Risk, Percentage
Non-controlling Interest
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]
Schedule of entity's financial statement activity related to Silver Creek during these periods
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]
Schedule of non-controlling interest in subsidiary
Construction in Progress [Member]
Construction in process
Contractual Obligation, Due in Second Year
2014
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]
Schedule of future minimum payments under the loans payable
Contractual Obligation, Due in Fourth Year
2016
Contractual liability
Contractual Obligation, Due in Next Twelve Months
Contractual Obligation, Due in Third Year
2015
Contractual Obligation, Fiscal Year Maturity [Abstract]
Future minimum payments under the loans payable
Convertible preferred stock converted into common stock (in shares)
Conversion of Stock, Shares Issued
Conversion of Stock, Amount Converted
Conversion of convertible preferred stock to common stock
Convertible Preferred Stock, Shares Reserved for Future Issuance
Conversion of Series B, Series C, Series D, Series E, Series F and Series G convertible preferred stock
Convertible Preferred Stock [Member]
Convertible preferred stock
Series B-G convertible preferred stock
Convertible notes
Convertible Notes Payable [Member]
Silver Creek Convertible Note
Corporate Debt Securities [Member]
Corporate debt securities
Costs and Expenses [Abstract]
Operating expenses:
Costs and Expenses
Total operating expenses
Total operating expenses
Credit risk
Credit Concentration Risk [Member]
Sales risk
Customer Concentration Risk [Member]
Damages from Product Defects [Member]
Quality control issues related to fill-finish manufacturing services
Description of reference rate that is added to stated percentage rate in calculation of variable rate
Debt Instrument, Description of Variable Rate Basis
Long-term Debt, Gross
Total loans payable outstanding at the end of the period
Debt Instrument [Line Items]
Debt
Nature of the business
Schedule of Long-term Debt Instruments [Table]
Debt [Member]
Debt
Debt Disclosure [Text Block]
Debt
Debt
Debt, Long-term and Short-term, Combined Amount
Total carrying amount of the liability components of the loans payable and the convertible notes
Outstanding borrowings
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Minimum stated percentage rate (as a percent)
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum
Debt Instrument, Periodic Payment, Interest
Contractual interest coupon payment
Debt Instrument, Increase, Additional Borrowings
Debt issued
Aggregate principal amounts
Debt Instrument, Unamortized Discount
Unamortized discount
Debt discounts
Debt, Current
Less current portion
Maximum interest rate on term loan (as a percent)
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum
Debt Related Commitment Fees and Debt Issuance Costs
Amortization of debt facility charge and commitment fee
Debt Instrument, Interest Rate, Stated Percentage
Interest rate (as a percent)
Depreciation
Deferred Tax Assets, Property, Plant and Equipment
Options to purchase common stock
Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance
Title of Individual [Axis]
Deferred tax incentives
Deferred Credits and Other Liabilities, Current
Deferred tax incentives
Deferred Credits and Other Liabilities, Noncurrent
Deferred Charges, Policy [Policy Text Block]
Deferred Financing Costs
Deferred rent
Deferred Rent Credit, Noncurrent
Deferred Revenue
Deferred revenues
Deferred revenue
Deferred financing costs
Deferred Finance Costs, Current, Net
Deferred rent
Deferred Rent Credit, Current
Deferred Costs, Current [Abstract]
Deferred Financing Costs
Net deferred taxes
Deferred Tax Assets, Net
Deferred tax assets
Deferred Tax Assets, Gross [Abstract]
Total gross deferred tax asset
Deferred Tax Assets, Gross
Deferred revenue
Deferred Tax Assets, Deferred Income
Deferred revenues
Deferred Revenue, Noncurrent
Deferred revenues
Deferred Revenue, Current
Net operating losses
Deferred Tax Assets, Operating Loss Carryforwards
Others
Deferred Tax Assets, Other
Accrued expenses
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
Credit carryforwards
Deferred Tax Assets, Tax Credit Carryforwards
Deferred compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Intangible assets
Deferred Tax Liabilities, Intangible Assets
Company's contributions to 401(k) defined contribution savings plan
Defined Contribution Plan, Employer Discretionary Contribution Amount
Depreciation and amortization
Depreciation, Depletion and Amortization
Depreciation
Depreciation
Derivative liability
Derivative Financial Instruments, Liabilities [Member]
Summary of significant accounting policies
Derivative [Line Items]
Derivative liability
Derivative Financial Instruments, Liabilities, Fair Value Disclosure
Derivative Liability
Derivative [Table]
Derivative Liability
Derivatives, Policy [Policy Text Block]
Director
Director [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Stock-Based Compensation
Stock-Based Compensation
Series B dividends declared
Dividends, Preferred Stock, Stock
Dividends, Preferred Stock, Cash
Cash dividends payable to Series B convertible preferred stock holders
Dividends Payable
Dividends on Series B convertible preferred stock declared but not paid
Accrued dividends on preferred stock paid in cash
Dividends payable
Dividends Payable, Current
Accrued dividends payable
Earnings Per Share, Basic and Diluted [Abstract]
Denominator:
Earnings Per Share, Basic and Diluted
Net loss per share available to common stockholders-basic and diluted (in dollars per share)
Net loss per share available to common stock holders-basic and diluted (in dollar per share)
Earnings Per Share [Text Block]
Net Loss Per Common Share
Net Loss Per Common Share
Reconciliation of the Company's effective tax rate to the statutory federal income tax rate
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Effective income tax rate (as a percent)
Effective Income Tax Rate, Continuing Operations
Foreign rate differentials (as a percent)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential
Federal statutory rate (as a percent)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate
Permanent differences (as a percent)
Effective Income Tax Rate Reconciliation, Nondeductible Expense
State taxes, net of Federal benefit (as a percent)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes
Change in valuation allowance (as a percent)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance
Stock compensation (as a percent)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost
Tax credits (as a percent)
Effective Income Tax Rate Reconciliation, Tax Credits
Other (as a percent)
Effective Income Tax Rate Reconciliation, Other Adjustments
Embedded Derivative, Fair Value of Embedded Derivative Liability
Derivative liability
Employee-related Liabilities, Current
Accrued payroll and related benefits
Weighted average period over which unrecognized compensation cost is expected to be recognized
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation
Allocation of recognized period cost
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]
Unrecognized compensation cost related to nonvested stock awards
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options
Lab equipment
Equipment [Member]
Convertible Preferred Stock
Equity Component [Domain]
Convertible Preferred Stock and Convertible Preferred Stock Warrants
Features of Convertible Preferred Stock [Abstract]
Measurement Frequency [Axis]
Fair Value Inputs, Probability of Default
Point Estimate (as a percent)
Fair Value, Hierarchy [Axis]
Liability Class [Axis]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Quantitative information associated with the fair value measurement of the Level 3 inputs:
Fair Value, Measurements, Recurring [Member]
Recurring basis
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Balance at the beginning of the period
Balance at the end of the period
Fair Value Inputs, Liabilities, Quantitative Information [Table]
Fair Value, Measurement Frequency [Domain]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value by Liability Class [Domain]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
Portion of convertible notes issued in February 2013 allocated to derivative
Fair Value, Measurements, Fair Value Hierarchy [Domain]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issues
Reclassification to common stock warrants
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]
Schedule of quantitative information associated with the fair value measurement of the Company's Level 3 inputs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets and liabilities measured at fair value on a recurring basis
Fair Value of Financial Instruments
Fair Value Disclosures [Text Block]
Fair Value of Financial Instruments
Fair Value, Inputs, Level 3 [Member]
Level 3
Fair Value, Inputs, Level 1 [Member]
Level 1
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss) Included in Other Income
Unrealized gain included in other income (expense)
Fair Value, Inputs, Level 2 [Member]
Level 2
Realized gain
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Roll-forward of the fair value of the derivative liability categorized as Level 3 instruments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of fair value of the derivative liability categorized as Level 3 instruments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value of Financial Instruments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Financing [Domain]
Financing [Axis]
Finite-Lived Intangible Assets, Major Class Name [Domain]
2017
Finite-Lived Intangible Assets, Amortization Expense, Year Five
2015
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Expected amortization expenses for the next five-year period:
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Finite-Lived Intangible Assets by Major Class [Axis]
2013
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
2016
Finite-Lived Intangible Assets, Amortization Expense, Year Four
2014
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Intangible assets
Finite-lived Intangible Assets [Roll Forward]
Intangible assets, net
Finite-Lived Intangible Assets, Net
Balance at the beginning of the period
Balance at the end of the period
Furniture and fixtures
Furniture and Fixtures [Member]
Loss on impairment and sales of assets
Gain (Loss) on Sale of Assets and Asset Impairment Charges
Gain (Loss) on Sale of Property Plant Equipment
Gain on disposal of property and equipment
Gross amount of fully depreciated fixed assets disposed
General and Administrative Expense
General and administrative
General and Administrative Expense [Member]
General and administrative
Goodwill
Goodwill
Goodwill and Intangible Assets
Goodwill and Intangible Assets, Policy [Policy Text Block]
Goodwill and Intangible Assets Disclosure [Text Block]
Goodwill and Intangible Assets, Net
Goodwill
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill and Intangible Assets, Net
Condensed Consolidated Statements of Comprehensive Loss
Income Tax Disclosure [Text Block]
Income Taxes
Income Taxes
Income Tax Authority [Axis]
Income Tax Authority [Domain]
Loss attributable to non-controlling interest
Income (Loss) Attributable to Noncontrolling Interest
Income Taxes
Income Tax, Policy [Policy Text Block]
Increase (Decrease) in Accounts Payable
Accounts payable
Temporary equity
Increase (Decrease) in Temporary Equity [Roll Forward]
Deferred revenues
Increase (Decrease) in Deferred Revenue
Accounts payable, accrued expenses and other
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities
Increase (Decrease) in Other Operating Assets and Liabilities, Net
Other assets and liabilities, net
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets
Accounts receivable
Increase (Decrease) in Receivables
Increase (decrease) in stockholders' equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
In-process research and development
Indefinite-Lived Intangible Assets (Excluding Goodwill)
IPR&D
IPR & D
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived Intangible Assets by Major Class [Axis]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
IPR & D
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]
Accrued interest
Interest Payable, Current
Interest Costs Capitalized
Capitalized interest
Interest expense
Cash and noncash interest expense
Interest Expense
Interest Costs Incurred [Abstract]
Interest expense incurred on loans payable, convertible notes payable, and other interest expense
Interest Costs Incurred
Total interest expense
Interest Expense, Other
Other interest expense
Interest Paid
Cash paid for interest
Federal
Internal Revenue Service (IRS) [Member]
Investment Income, Interest
Interest income
Investment
Investment Tax Credit Carryforward [Member]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Marketable Securities
Marketable Securities
Initial public offering
IPO [Member]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Axis]
Leasehold improvements
Leasehold Improvements [Member]
Leases, Operating [Abstract]
Operating Leases
Total current liabilities
Liabilities, Current
Liabilities, Current [Abstract]
Current liabilities:
Total liabilities
Liabilities
Total liabilities of consolidated subsidiaries
Liabilities, Non-Controlling Interest (Deficit) and Stockholders' Deficit
Liabilities and Equity [Abstract]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities
Total liabilities, non-controlling interest (deficit) and stockholders' deficit
Liabilities and Equity
Loans Payable, Current
Loans payable
Loans Payable, Fair Value Disclosure
Loans payable
Long-term Debt, Current Maturities
Current portion of long-term debt
Long-term Debt, Excluding Current Maturities
Loans payable, net of current portion
Loans Payable, Noncurrent
Loans payable
Loss Contingencies [Table]
Loss Contingency Nature [Axis]
Loss Contingency, Nature [Domain]
Major Customers [Axis]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]
Available-for-Sale Securities
Marketable Securities, Policy [Policy Text Block]
Marketable Securities
Marketable Securities [Abstract]
Marketable Securities
Marketable Securities, Current
Available-for-sale securities
Maximum [Member]
Maximum
Minimum [Member]
Minimum
Noncontrolling Interest [Table]
Noncontrolling Interest [Line Items]
Consolidated subsidiaries
Non-controlling Interest (Deficit)
Principles of consolidation
Noncontrolling Interest, Ownership Percentage by Parent
Ownership interest (as a percent)
Money Market Funds, at Carrying Value
Cash equivalents - money market funds
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Activity related to Non-controlling Interest (Deficit)
Name of Major Customer [Domain]
Nature of the Business
Nature of Operations [Text Block]
Cash flows from financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Cash flows from operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net Cash Provided by (Used in) Continuing Operations
Net decrease in cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Net cash (used in) provided by investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Net Income (Loss) Available to Common Stockholders, Basic
Net loss available to common stockholders - basic
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Numerator - diluted:
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Numerator - basic:
Net Income (Loss) Available to Common Stockholders, Diluted
Net loss available to common stockholders - diluted
Net cash (used in) provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Cash flows from investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Net Income (Loss) Attributable to Parent
Net loss attributable to Merrimack Pharmaceuticals, Inc.
Net loss attributable to Merrimack Pharmaceuticals, Inc.
Net Income (Loss) Attributable to Noncontrolling Interest
Less net loss attributable to non-controlling interest
Loss attributable to non-controlling interest
Net loss attributable to Silver Creek
Recent Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Non-cash investing and financing activities
Noncash Investing and Financing Items [Abstract]
Other income and expenses
Nonoperating Income (Expense) [Abstract]
Other Income (Expense)
Number of operating segments
Number of Operating Segments
Temporary equity, non-controlling interest
Noncontrolling Interest [Member]
Future minimum lease payments under noncancelable operating leases
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating Loss Carryforwards [Table]
NOL
Operating Loss Carryforwards
Operating Leases, Rent Expense, Net
Total rent expense
Operating Income (Loss)
Loss from operations
2015
Operating Leases, Future Minimum Payments, Due in Three Years
2014
Operating Leases, Future Minimum Payments, Due in Two Years
2013
Operating Leases, Future Minimum Payments Due, Next Twelve Months
2016
Operating Leases, Future Minimum Payments, Due in Four Years
Operating loss carryforwards
Operating Loss Carryforwards [Line Items]
2017
Operating Leases, Future Minimum Payments, Due in Five Years
Nature of the Business
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Other assets
Other Assets, Noncurrent
Accrued goods and services
Other Liabilities, Current
Other Nonoperating Income (Expense)
Other, net
Other income
Plus: Unaccreted dividends on convertible preferred stock
Other Preferred Stock Dividends and Adjustments
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Other comprehensive income:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Other comprehensive income
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Unrealized gain on available-for-sale securities
Non-cash interest expense
Paid-in-Kind Interest
Temporary equity, parent
Parent [Member]
Accounts Payable, Accrued Expenses and Other
Other investing activities, net
Payments for (Proceeds from) Other Investing Activities
Deferred financing costs
Payments of Stock Issuance Costs
Issuance cost for shares issued to other investors
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Payments of dividends on Series B convertible preferred stock
Payments of Ordinary Dividends, Preferred Stock and Preference Stock
Accrued dividends on preferred stock paid in cash
Payments of Ordinary Dividends
Dividends declared and paid
Plan Name [Domain]
Plan Name [Axis]
Preferred Stock, Value, Issued
Preferred stock, $0.01 par value: 10,000 shares authorized at December 31, 2012 and March 31, 2013; no shares issued or outstanding at December 31, 2012 and March 31, 2013
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Issuance of dividends (in shares)
Preferred Stock Dividends, Shares
Preferred Stock, Dividend Rate, Percentage
Annual cumulative dividend rate (as a percent)
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Reclassifications
Reclassification, Policy [Policy Text Block]
Proceeds from exercise of stock warrants
Proceeds from Warrant Exercises
Proceeds from issuance of common stock upon exercise of stock warrants
Proceeds from issuance of loans payable, net of issuance costs
Proceeds from Debt, Net of Issuance Costs
Net proceeds from loan
Proceeds from Issuance of Secured Debt
Proceeds from shares issued to other investors
Proceeds from Noncontrolling Interests
Proceeds from issuance of convertible preferred stock, net of offering costs
Proceeds from Issuance of Convertible Preferred Stock
Proceeds from issuance of common stock
Proceeds from Issuance of Common Stock
Aggregate gross proceeds from a firm commitment underwritten initial public offering for shares of common stock
Proceeds from maturities of available-for-sale securities
Proceeds from Sale and Maturity of Marketable Securities
Purchases of property and equipment
Proceeds from Sale of Property, Plant, and Equipment
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net loss
Property, Plant and Equipment, Disposals
Gross amount of fully depreciated fixed assets disposed
Disposal of fully depreciated assets
Estimated useful life
Property, Plant and Equipment, Useful Life
Property, Plant and Equipment, Type [Domain]
Property and Equipment, Net
Property and Equipment
Property, Plant and Equipment, Policy [Policy Text Block]
Property and equipment, net
Property, Plant and Equipment, Net
Property and equipment, net
Property and Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, net
Property, Plant and Equipment, Gross
Property and equipment, gross
Schedule of estimated useful lives of property and equipment including leasehold improvements
Property, Plant and Equipment [Table Text Block]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment, Net
Selected Quarterly Financial Data (Unaudited)
Quarterly Financial Information [Text Block]
Range [Axis]
Range [Domain]
Accounts receivable
Receivables, Net, Current
Redeemable Convertible Preferred Stock [Member]
Series B-G convertible preferred stock
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Related Party Transaction [Line Items]
Related Party Transactions
Related Party [Domain]
Related Party Transactions
Related Party [Axis]
Repayments of Long-term Capital Lease Obligations
Principal payments on capital lease obligations
Research and Development Expense
Research and development
Research and development expenses
Research and development
Research Tax Credit Carryforward [Member]
Research and Development Expense [Member]
Research and development
Research and Development Expenses
Research and Development Expense, Policy [Policy Text Block]
Restricted Cash and Cash Equivalents
Restricted cash
Restricted cash
Restricted Cash and Cash Equivalents, Current
Restricted cash
Restricted Cash and Cash Equivalents, Noncurrent
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings [Member]
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
Collaboration revenues
Revenues
Revenue recognized
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price
Weighted average exercise price (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Exercisable at the end of the period (in dollars)
Options exercisable (in dollars)
Vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Expected term
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term
Weighted average remaining contractual life
Exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Outstanding at the end of the period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Outstanding at the beginning of the period
Outstanding at the end of the period
Weighted average remaining contractual life
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term
Scenario, Unspecified [Domain]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of assets and liabilities measured at fair value on a recurring basis
Schedule of revenue recognized and assets and liabilities under collaborative arrangements
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Summary of stock option activity
Schedule of Comprehensive Income (Loss) [Table Text Block]
Schedule of comprehensive loss from operations
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of assumptions used to calculate fair value of options granted to employees
Schedule of Debt [Table Text Block]
Schedule of debt
Schedule of Available-for-sale Securities [Table]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of computation of basic and diluted net loss per share available to common stockholders
Schedule of changes in the carrying value of goodwill, IPR&D and intangible assets
Schedule of Intangible Assets and Goodwill [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares
Schedule of reconciliation of the Company's effective tax rate to the statutory federal income tax rate
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule of expected amortization expense for intangible assets for the next five-year period
Schedule of Expected Amortization Expense [Table Text Block]
Schedule of future minimum lease payments under noncancelable operating leases
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Schedule of consideration transferred and the amounts of identified assets acquired and liabilities assumed
Schedule of Purchase Price Allocation [Table Text Block]
Schedule of quarterly financial information
Schedule of Quarterly Financial Information [Table Text Block]
Schedule of temporary differences that give rise to significant net deferred tax assets
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Unrealized Loss on Investments [Table Text Block]
Schedule of available-for-sale securities in an unrealized loss position
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Schedule of accounts payable, accrued expenses and other
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]
Schedule of available-for-sale securities
Schedule of available-for-sale securities, all of which have maturities of twelve months or less
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Summary of range of exercise prices for stock options outstanding and exercisable
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Short-term Debt [Table Text Block]
Schedule of debt
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Property, Plant and Equipment [Table]
Schedule of Stock by Class [Table Text Block]
Schedule of convertible preferred stock
Loan and Security Agreement
Secured Debt [Member]
Segment and Geographic Information
Segment Reporting, Policy [Policy Text Block]
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Segment and Geographic Information
Selected Quarterly Financial Data (Unaudited)
Series A Preferred Stock
Series A Preferred Stock [Member]
Series E Preferred Stock [Member]
Series E Preferred Stock
Series D Preferred Stock [Member]
Series D Preferred Stock
Series G preferred stock
Series G Preferred Stock [Member]
Series G Preferred Stock
Series C convertible preferred stock
Series C Preferred Stock [Member]
Series C preferred stock
Series C Preferred Stock
Series B preferred stock
Series B Preferred Stock [Member]
Series B Preferred Stock
Series F preferred stock
Series F Preferred Stock [Member]
Series F Preferred Stock
Stock-based compensation
Share-based Compensation
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Additional common stock available for issuance (in shares)
Additional shares of common stock registered (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period
Vesting period
Stock options issued (in shares)
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation
Assumptions for valuation of option granted
Share Price
Public offering price (in dollars per share)
Share offering price (in dollars per share)
Granted (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercised (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility (as a percent)
Weighted average exercise price for exercisable option
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Exercisable at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield (as a percent)
Aggregate intrinsic value of options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Additional disclosures
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Exercisable at the end of the period (in shares)
Number of stock option exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Shares of common stock available for grant (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Shares of common stock registered
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Assumptions used to estimate grant date fair value of options granted
Weighted average assumptions used for determining fair value of options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Forfeited (in shares)
Options vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Number of shares exercisable
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options
Exercise Price Range [Axis]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Vested and expected to vest at the end of the period (in shares)
Number of shares vested and expected to vest
Number of shares
Stock options outstanding and exercisable
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)
Outstanding at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Outstanding at the beginning of the period (in dollars)
Outstanding at the end of the period (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Vested and expected to vest at the end of the period (in dollars)
Shares vested and expected to vest (in dollars)
Number of shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Outstanding at the beginning of the period (in shares)
Outstanding at the end of the period (in shares)
Award Type [Domain]
Stock-Based Compensation
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Vested and expected to vest at the end of the period (in dollars per share)
Weighted average exercise price of shares vested and expected to vest
Weighted average exercise price (in dollars per share)
Stock-based compensation expense for non-employee awards
Share-based Goods and Nonemployee Services Transaction, Expense
Balance ( in shares )
Balance (in shares)
Shares, Issued
Balance (in shares)
Balance (in shares)
Shares, Outstanding
Short-term Debt
Net carrying amount of the liability component of convertible notes
Outstanding borrowings
State
State and Local Jurisdiction [Member]
Statement [Table]
Scenario [Axis]
Common stock
Statement [Line Items]
Consolidated Statements of Convertible Preferred Stock, Non-controlling Interest and Stockholders' Deficit
Condensed Consolidated Statements of Cash Flows
Equity Components [Axis]
Condensed Consolidated Balance Sheets
Class of Stock [Axis]
Stock Issued During Period, Value, Dividend Reinvestment Plan
Issuance of dividends
Stock Issued During Period, Shares, Period Increase (Decrease)
Stock Issued During Period, Shares, Acquisitions
Issuance of common stock in connection with acquisition (in shares)
Stock Options [Member]
Options to purchase common stock
Stock options
Exercise of stock options
Stock Issued During Period, Value, Stock Options Exercised
Stock Issued During Period, Value, Acquisitions
Issuance of common stock in connection with acquisition
Stock Issued During Period, Value, New Issues
Issuance of Series F stock
Initial public offering, net of offering costs
Stock Issued During Period, Value, Conversion of Convertible Securities
Issuance of Series C stock as a result of warrant exercises
Conversion of convertible preferred stock into common stock
Aggregate shares of common stock sold in connection with initial public offering (in shares)
Stock Issued During Period, Shares, New Issues
Initial public offering, net of offering costs (in shares)
Issuance of Series F stock (in shares)
Exercise of employee stock options (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Exercised (in shares)
Exercise of stock options (in shares)
Stock Issued During Period, Shares, Conversion of Convertible Securities
Issuance of Series C stock as a result of warrant exercises (in shares)
Conversion of convertible preferred stock into common stock (in shares)
Stock-based compensation (in shares)
Stock Issued During Period, Shares, Share-based Compensation, Gross
Stockholders' deficit:
Stockholders' Equity Attributable to Parent [Abstract]
Accumulated other comprehensive income (loss)
Stockholders' Equity, Policy [Policy Text Block]
Total stockholders' deficit
Stockholders' Equity Attributable to Parent
Balance
Balance
Common Stock
Stockholders' Equity, Period Increase (Decrease)
Subsequent Events [Text Block]
Subsequent Events
Subsequent Events
Subsequent Event Type [Domain]
Subsequent event
Subsequent Event [Line Items]
Subsequent Event Type [Axis]
Subsequent Event [Table]
Subsequent events
Subsequent Event [Member]
Schedule of changes in the valuation allowance
Summary of Valuation Allowance [Table Text Block]
Supplemental disclosure of cash flows
Supplemental Cash Flow Information [Abstract]
Amount of tax credit carryforward
Tax Credit Carryforward, Amount
Tax Credit Carryforward, Name [Domain]
Tax credit carryforward
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward [Table]
Temporary Equity, Liquidation Preference Per Share
Liquidation preference (in dollars per share)
Initial investment recorded as convertible preferred stock (in dollars per share)
Issuance of stock
Temporary Equity, Stock Issued During Period, Value, New Issues
Temporary Equity, Carrying Amount, Attributable to Parent
Convertible preferred stock
Carrying value
Net loss attributable to Silver Creek
Loss attributable to non-controlling interest
Temporary Equity, Net Income
Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests
Balance
Balance
Temporary Equity [Line Items]
Convertible preferred stock
Balance at the beginning of the period
Balance at the end of the period
Temporary Equity, Carrying Amount, Attributable to Noncontrolling Interest
Temporary Equity, Number of Shares, Redemption Value and Other Disclosures [Abstract]
Liquidation preference and conversion
Temporary Equity, Shares Issued
Shares Outstanding
Shares issued
Number of shares issued
Balance (in shares)
Balance (in shares)
Temporary Equity, Redemption Price Per Share
Conversion price (in dollars per share)
Temporary Equity, by Class of Stock [Table]
Title of Individual with Relationship to Entity [Domain]
Type of Arrangement and Non-arrangement Transactions [Axis]
Unbilled Contracts Receivable
Accounts receivable, unbilled
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
US Government Agencies Debt Securities [Member]
U.S. government agencies securities
Treasury funds
US Treasury Securities [Member]
Valuation Technique [Axis]
Valuation allowance on deferred tax assets
Balance at beginning of period
Balance at end of period
Valuation Allowance, Amount
Valuation Technique [Domain]
Common stock warrants
Warrant [Member]
Stock Warrants
Weighted Average Number of Shares Outstanding, Basic and Diluted
Weighted-average common shares used in computing net loss per share available to common stockholders-basic and diluted (in shares)
Weighted-average common shares-basic and diluted
Aggregate principal amount of loans received
Debt Instrument, Face Amount
Debt Instrument Number of Tranches
Represents the number of tranches in which amount was borrowed by the entity.
Number of tranches in which amount was borrowed
Interest expense
Interest Expense, Debt
Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
The amount of stock issuance costs capitalized which were included in accounts payable or accrued and other expenses.
Changes in deferred financing costs included in ending accounts payable, accrued expenses and other
Other financing activities, net
Proceeds from (Payments for) Other Financing Activities
Represents the number of novel therapeutic oncology candidates in clinical development of the entity.
Number of novel therapeutic oncology candidates
Number of Novel Therapeutic Oncology Candidates in Clinical Development
Amounts reclassified out of accumulated other comprehensive income
Amount, after tax, of reclassification adjustments of other comprehensive income (loss).
Reclassification from Accumulated Other Comprehensive Income Current Period Net of Tax
Collaborative Arrangement Deferred Revenue Recognized Due To Change In Estimate
Represents the deferred revenue recognized during the period under the terms of the license agreement due to a change in estimate of expected development term.
Deferred revenue recognized due to a change in estimate of expected development term
Operating Leases Reimbursement For Tenant Improvements Outstanding Amount
Represents the outstanding balance at the end of the period of tenant improvements reimbursable by landlord under the lease agreement.
Aggregate landlord reimbursable tenant improvements outstanding under the existing lease and the lease amendment
Operating Leases Additional Reimbursement For Tenant Improvements
Represents the additional amount of tenant improvements agreed to be reimbursed by landlord under the lease amendment.
Additional reimbursement for tenant improvements agreed by landlord per lease amendment
Gain Loss On Mark To Market On Preferred Stock Warrants Non-cash
The non-cash impact on the cash flow of the unrealized gain or loss on the remeasurement of fair value of preferred stock warrants.
Remeasurement of convertible preferred stock warrants